Meeting
2018 Genitourinary Cancers Symposium
Adjuvant etoposide plus cisplatin (EP) for pathologic stage (PS) II nonseminomatous germ cell tumor (NSGCT).
Authors
Deaglan Joseph McHugh
Memorial Sloan Kettering Cancer Center, New York, NY
Deaglan Joseph McHugh , Samuel Funt , Deborah Silber , Andrea Knezevic , Sujata Patil , Devon O'Donnell , Stephanie Tsai , Victor E. Reuter , Joel Sheinfeld , Brett Stewart Carver , Robert J. Motzer , Dean F. Bajorin , George J. Bosl , Darren R. Feldman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Penile, Urethral, and Testicular Cancers
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 567)
DOI
10.1200/JCO.2018.36.6_suppl.567
Abstract #
567
Poster Bd #
M4
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Adjuvant etoposide plus cisplatin (EP) for pathologic stage (PS) II nonseminomatous germ cell tumor (NSGCT).
First Author: Deaglan Joseph McHugh
Poster
2018 ASCO Annual Meeting
Etoposide and cisplatin (EP) for metastatic good-risk germ cell tumors (GCTs): The Memorial Sloan-Kettering Cancer Center (MSKCC) experience in 944 patients (pts).
First Author: Samuel Funt
Poster
2021 ASCO Annual Meeting
Efficacy of TIP (paclitaxel, ifosfamide and cisplatin) as salvage chemotherapy for relapsed germ cell cancer patients stratified by the modified International Prognostic Factors Study Group (IPFSG) score: The Northern Ireland (NI) Experience.
First Author: Adam Uprichard
Poster
2015 Genitourinary Cancers Symposium
Risk-stratified treatment of patients with metastatic germ cell tumor with progression after first-line therapy.
First Author: Orvar Gunnarsson